A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Trial details
- Registry ID
- NCT05002127
- Phase
- Phase 2, Phase 3
The FDA approved Ramucirumab (Cyramza) on 21 Apr 2014.
Drug identity checked against registry records
Also recorded as Cyramza
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127 | ALX Oncology Inc. | Phase 2, Phase 3 | Completed | 2024-05-24Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-04-21Day | Ramucirumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125477", "applicant_as_listed_by_fda": "ELI LILLY AND CO", "brand_names": ["CYRAMZA"], "active_ingredients": ["RAMUCIRUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140421", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |